U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06890429) titled 'Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults' on March 17.
Brief Summary: The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
Study Start Date: Dec. 07, 2023
Study Type: INTERVENTIONAL
Condition:
Respiratory Synctial Virus Infections
Intervention:
BIOLOGICAL: RSV/Flu-01E
Participants will receive single intranasal injection of RSV/Flu-01E vaccine in 0.5 ml, containing 8.4 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vec...